About Lysosomal alpha-glucosidase
Lysosomal alpha-glucosidase (GAA) is a protein
from Homo sapiens identified by UniProt accession
P10253, 952 residues long.
MolForge cross-references it against 0 known binders and
526 disease associations.
Target properties
| Protein name | Lysosomal alpha-glucosidase |
|---|
| UniProt accession | P10253 |
|---|
| Gene | GAA |
|---|
| Organism | Homo sapiens |
|---|
| Length | 952 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (5)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (526)
Diseases linked to this target (Open Targets).
- glycogen storage disease II · score 0.87
- Glycogen storage disease due to acid maltase deficiency · score 0.83
- glycogen storage disease due to acid maltase deficiency, infantile onset · score 0.59
- type 2 diabetes mellitus · score 0.58
- Abnormality of the cardiovascular system · score 0.52
- disorder of glycogen metabolism · score 0.51
- Glycogen storage disease due to acid maltase deficiency, adult onset · score 0.50
- diabetes mellitus · score 0.46
- glycogen storage disease due to acid maltase deficiency, late-onset · score 0.46
- reticulocyte count · score 0.40
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P10253-F1 | alphafold | PREDICTED | 91.89 | — |
Amino-acid sequence (952 residues)
MGVRHPPCSH RLLAVCALVS LATAALLGHI LLHDFLLVPR ELSGSSPVLE ETHPAHQQGA SRPGPRDAQA HPGRPRAVPT QCDVPPNSRF DCAPDKAITQ EQCEARGCCY IPAKQGLQGA QMGQPWCFFP PSYPSYKLEN LSSSEMGYTA TLTRTTPTFF PKDILTLRLD VMMETENRLH FTIKDPANRR YEVPLETPHV HSRAPSPLYS VEFSEEPFGV IVRRQLDGRV LLNTTVAPLF FADQFLQLST SLPSQYITGL AEHLSPLMLS TSWTRITLWN RDLAPTPGAN LYGSHPFYLA LEDGGSAHGV FLLNSNAMDV VLQPSPALSW RSTGGILDVY IFLGPEPKSV VQQYLDVVGY PFMPPYWGLG FHLCRWGYSS TAITRQVVEN MTRAHFPLDV QWNDLDYMDS RRDFTFNKDG FRDFPAMVQE LHQGGRRYMM IVDPAISSSG PAGSYRPYDE GLRRGVFITN ETGQPLIGKV WPGSTAFPDF TNPTALAWWE DMVAEFHDQV PFDGMWIDMN EPSNFIRGSE DGCPNNELEN PPYVPGVVGG TLQAATICAS SHQFLSTHYN LHNLYGLTEA IASHRALVKA RGTRPFVISR STFAGHGRYA GHWTGDVWSS WEQLASSVPE ILQFNLLGVP LVGADVCGFL GNTSEELCVR WTQLGAFYPF MRNHNSLLSL PQEPYSFSEP AQQAMRKALT LRYALLPHLY TLFHQAHVAG ETVARPLFLE FPKDSSTWTV DHQLLWGEAL LITPVLQAGK AEVTGYFPLG TWYDLQTVPV EALGSLPPPP AAPREPAIHS EGQWVTLPAP LDTINVHLRA GYIIPLQGPG LTTTESRQQP MALAVALTKG GEARGELFWD DGESLEVLER GAYTQVIFLA RNNTIVNELV RVTSEGAGLQ LQKVTVLGVA TAPQQVLSNG VPVSNFTYSP DTKVLDICVS LLMGEQFLVS WC
Explore Lysosomal alpha-glucosidase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets